research Alopecia: A review of laser and light therapies
This review discusses cases and research on paradoxical hair growth after laser hair removal and explores laser and light therapies for treating alopecia, but reports no new results.
Search
for
Sort by
Research
30 / 1000+ results 
research Lasers in Hair Growth and Hair Transplantation
This abstract describes the use of lasers in hair transplantation for creating recipient sites and enhancing hair growth but reports no new findings.
research Illuminating current pitfalls in optimal photobiomodulation device development and assessment for treating hair loss
This article reviews the limitations in current research on photobiomodulation for hair regrowth and suggests that optimal wavelengths and dosing have not yet been identified, noting that recommending these devices may be premature.
research What to Look for in Red Light Therapy: A Product Guide Backed by Science
This review discusses the mechanisms, scientific support, and FDA clearance of photobiomodulation mask devices but reports no new research findings.
research US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions
This commentary explores the marketing of unproven and unlicensed adipose-derived stem cell treatments in US clinics, highlighting concerns about patient safety and regulatory challenges.
research Laser for Hair Removal
This review discusses the factors affecting laser hair removal results and adverse events, emphasizing the need for more research to determine optimal treatment parameters; it reports no new clinical findings.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.
research Photobiomodulation for the management of hair loss
This review discusses photobiomodulation as a potential treatment for hair loss, highlighting its safety and possible effectiveness but noting cost, protocol standardization, and expectation management as limitations; it reports no new clinical results.
research Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies
This article discusses the emerging field of supportive oncodermatology, which collaborates between oncology and dermatology to address skin-related side effects of cancer treatments, and reports no new clinical results.
research Editorial Note on Next-Generation Therapies and Advance Acne Treatment
This study reported that clascoterone cream reduced inflammatory and noninflammatory acne lesions in a trial with 1440 white males and non-pregnant females, showing it was well tolerated in these participants.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
This review examines the use of apremilast for non-FDA-approved dermatological conditions, noting varied efficacy but a favorable safety profile compared to conventional treatments.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
This study confirms known risks of cladribine and reveals potential new safety concerns, emphasizing the need for careful monitoring for early acute toxicity.
research Photobiomodulation therapy for androgenetic alopecia: A clinician’s guide to home-use devices cleared by the Federal Drug Administration
This review identifies FDA-cleared home-use photobiomodulation devices for androgenetic alopecia treatment and highlights their excellent safety profile but notes the lack of long-term comparative studies.
research Low level laser therapy and hair regrowth: an evidence-based review
This review concluded that FDA-cleared low-level laser therapy devices are safe and effective for patients with male and female pattern hair loss who do not respond to or tolerate standard treatments.
research Androgenetic alopecia (male pattern hair loss) in the United States: What treatments should primary care providers recommend?
This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.
research Medical treatments for male and female pattern hair loss
This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.
research Low‐level laser (light) therapy (LLLT) for treatment of hair loss
This review discusses the potential mechanisms and evidence supporting low-level laser therapy for stimulating hair growth in men and women, while noting its safety and effectiveness but needing further study on specific parameters.
research Bidirectional Barbed Sutures for Wound Closure: Evolution and Applications
This narrative review discusses the advantages of bidirectional barbed sutures in wound closure, such as faster placement and no need for knots, but reports no new clinical results.
research Applications and Risks of Nanomaterials Used in Regenerative Medicine, Delivery Systems, Theranostics, and Therapy
This review classifies engineered nanomaterials by composition and application in biomedicine, highlighting diverse uses like regenerative medicine and potential occupational side effects, but reports no new clinical results.
research Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis
This case report highlights a severe kidney injury linked to the combined use of ciclosporin and simvastatin in a patient treated for alopecia universalis.
research Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.
research Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.
research Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
This study found that the type of reporter significantly influences the detection of cancer therapy-induced alopecia signals, highlighting differences in signal amplification between patients and healthcare professionals.
research A Simple Decision Tree Suited for Identification of Early Oral Drug Candidates With Likely Pharmacokinetic Nonlinearity by Intestinal CYP3A Saturation
This study suggests a decision tree using in vitro metabolic clearance to identify early drug candidates likely to experience nonlinear pharmacokinetics due to intestinal CYP3A-related metabolism.
research Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
This review discusses advancements in skin microphysiological systems, such as 3D bioprinting, skin organoids, and skin-on-a-chip, and their effectiveness in emulating human skin functions for research and preclinical applications, highlighting the potential for replacing animal testing with these innovative technologies.
research Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
This study investigated paternal drug exposure using FDA data and identified significant associations with reproductive health risks, including congenital anomalies linked to immunosuppressive drugs, and emphasized specific risk combinations like biologics and abortion, diazepam and small for date baby, and finasteride and cryptorchidism.
research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.
research A Systematic Review and Meta-analysis of Randomized Controlled Trials of United States Food and Drug Administration-Approved, Home-use, Low-Level Light/Laser Therapy Devices for Pattern Hair Loss: Device Design and Technology.
This study found that FDA-approved low-level light/laser therapy devices significantly increased hair density in individuals with pattern hair loss compared to sham devices.
research Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.